Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
85%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
49%
Lung Cancer
41%
Pan-cancer Analysis
28%
Phase I Study
27%
Genome Analysis
26%
Tumor
19%
Overall Survival
18%
Carboplatin
17%
Pemetrexed
16%
In Cancer
15%
Phase II Trial
14%
Chemotherapy
14%
Small Cell Lung Cancer
13%
Human Cancer
12%
Targeted Therapy
12%
Cancer Types
11%
Cancer Genome Atlas
11%
Docetaxel
11%
Oncology
11%
Cisplatin
9%
Bevacizumab
9%
Lung Adenocarcinoma
9%
Progression-free Survival
9%
Previously Treated
9%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
8%
95% Confidence Interval
8%
Phase I Trial
8%
Brain Metastases
8%
Genetic Modification
7%
Adjuvant Chemotherapy
7%
Hazard Ratio
7%
Stable Disease
7%
Erlotinib
7%
Lung Squamous Cell Carcinoma
7%
Never-smokers
7%
Early-stage Lung Cancer
6%
Clinical Trials
6%
Molecular Characterization
6%
Paclitaxel
6%
Carboplatin/paclitaxel
6%
Radiation Therapy
6%
Maximum Tolerated Dose
6%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
6%
Stage III Non-small Cell Lung Cancer
6%
Clinical Practice Guidelines
6%
Platinum-based Chemotherapy
6%
Irinotecan
6%
Partial Response
6%
Randomized Phase II Trial
6%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Malignant Neoplasm
43%
Lung Cancer
37%
Diseases
22%
Overall Survival
21%
Chemotherapy
19%
Genetics
16%
Oncology
14%
Small Cell Lung Cancer
14%
Cancer
12%
Neoplasm
11%
Tumor
11%
Progression Free Survival
11%
Pemetrexed
10%
Radiation Therapy
10%
Targeted Therapy
10%
Clinical Trial
10%
Chemoradiotherapy
8%
Carboplatin
8%
Cisplatin
8%
Paclitaxel
8%
Adverse Event
7%
Adjuvant Chemotherapy
7%
Epidermal Growth Factor Receptor
7%
Arm
7%
Biological Marker
7%
Positron Emission Tomography
7%
Solid Malignant Neoplasm
6%
Clinical Oncology
6%
Immunotherapy
6%
Recurrent Disease
6%
Phase II Trials
6%
Metastatic Carcinoma
6%
Histology
6%
Gefitinib
5%
Esophageal Cancer
5%
Brain Metastasis
5%
Lung Adenocarcinoma
5%
Hazard Ratio
5%
Circulating Tumor DNA
5%
Next Generation Sequencing
5%
Xenograft
5%
Platinum
5%
Lung
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
84%
Chemotherapy Regimens
31%
Lung Cancer
29%
Diseases
21%
Small Cell Lung Cancer
19%
Carboplatin
16%
Malignant Neoplasm
16%
Overall Survival
14%
Paclitaxel
14%
Pemetrexed
12%
Clinical Trial
11%
Docetaxel
9%
Epidermal Growth Factor Receptor
9%
Bevacizumab
9%
Adverse Event
9%
Progression Free Survival
8%
Phase II Trials
8%
Platinum
7%
Neoplasm
7%
Solid Malignant Neoplasm
6%
Irinotecan
6%
Cisplatin
6%
Erlotinib
6%
Maximum Tolerated Dose
5%
Sotorasib
5%